Albert Guvenis

Prof. Albert Guvenis


Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2018 in Immunology
Verified
Journal Article
Closed access
PDF file
SDSultan Damgaci
Sultan Damgaci
AIArig Ibrahim‐Hashim
Arig Ibrahim‐Hashim
PEPedro M. Enriquez‐Navas
Pedro M. Enriquez‐Navas
SPShari Pilon‐Thomas
Shari Pilon‐Thomas
AGAlbert Guvenis
Albert Guvenis
RGRobert Gillies
Robert Gillies

1 March 2019 in Lung Cancer
Verified
Journal Article
Closed access
ITIlke Tunali
Ilke Tunali
JGJhanelle E. Gray
Jhanelle E. Gray
JQJin Qi
Jin Qi
MAMahmoud Abdalah
Mahmoud Abdalah
DJDaniel K. Jeong
Daniel K. Jeong
MSMatthew Schabath
Matthew Schabath

8 September 2019 in Medical Physics
Verified
Journal Article
Closed access
PDF file
ITIlke Tunali
Ilke Tunali
LHLawrence O. Hall
Lawrence O. Hall
SNSandy Napel
Sandy Napel
DCDmitry Cherezov
Dmitry Cherezov
AGAlbert Guvenis
Albert Guvenis
MSMatthew Schabath
Matthew Schabath

1 November 1982 in IEEE Transactions on Circuits and Systems
Verified
Journal Article
Closed access
RFR. Fischl
R. Fischl
THT. Halpin
T. Halpin
AGAlbert Guvenis
Albert Guvenis

13 May 2021 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
ITIlke Tunali
Ilke Tunali
YTYan Tan
Yan Tan
JGJhanelle E Gray
Jhanelle E Gray
EKEvangelia Katsoulakis
Evangelia Katsoulakis
SESteven Eschrich
Steven Eschrich
MSMatthew Schabath
Matthew Schabath
Background: Immunotherapy yields survival benefit for some advanced stage non-small cell lung cancer (NSCLC) patients. Because highly predictive biomarkers of immunotherapy response are an unmet clinical need, we used pretreatment radiomics and clinical data to train and validate a parsimonious model associated with survival outcomes among NSCLC patients treated with immunotherapy. Methods: Three cohorts of NSCLC patients treated with immunotherapy were analyzed: training (n = 180), validation 1 (n = 90), and validation 2 (n = 62). The most informative clinical and radiomic features were subjected to decision tree analysis, which stratified patients into risk groups of low, moderate, high, and very high risk of death after initiation of immunotherapy. All statistical tests were 2-sided. Results: The very high-risk group was associated with extremely poor overall survival (OS) in validation cohorts 1 (hazard ratio [HR] = 5.35, 95% confidence interval [CI] = 2.14 to 13.36; 1-year OS = 11.1%, 95% CI = 1.9% to 29.8%; 3-year OS = 0%) and 2 (HR = 13.81, 95% CI = 2.58 to 73.93; 1-year OS = 47.6%, 95% CI = 18.2% to 72.4%; 3-year OS = 0%) when compared with the low-risk group (HR = 1.00) in validation cohorts 1 (1-year OS = 85.0%, 95% CI = 60.4% to 94.9%; 3-year OS = 38.9%, 95% CI = 17.1% to 60.3%) and 2 (1-year OS = 80.2%, 95% CI = 40.3% to 94.8%; 3-year OS = 40.1%, 95% CI = 1.3% to 83.5%). The most informative radiomic feature, gray-level co-occurrence matrix (GLCM) inverse difference, was positively associated with hypoxia-related carbonic anhydrase 9 using gene-expression profiling and immunohistochemistry. Conclusion: Utilizing standard-of-care imaging and clinical data, we identified and validated a novel parsimonious model associated with survival outcomes among NSCLC patients treated with immunotherapy. Based on this model, clinicians can identify patients who are unlikely to respond to immunotherapy.

6 October 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
ITIlke Tunali
Ilke Tunali
OSOlya Stringfield
Olya Stringfield
AGAlbert Guvenis
Albert Guvenis
HWHua Wang
Hua Wang
YLYing Liu
Ying Liu
MSMatthew Schabath
Matthew Schabath
Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients Radial gradient and radial deviation radiomic features from pre-surgical CT scans are associated with survival among lung adenocarcinoma patients